Unicycive Therapeutics (UNCY) Net Margin (2022 - 2023)
Unicycive Therapeutics' (UNCY) quarterly Net Margin came in at 2187.7% in Q1 2023, down 274.39% on a QoQ basis from 584.33% in Q3 2022.
Unicycive Therapeutics (UNCY) Net Margin (2022 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has 2 years of Net Margin data on file, last reported at 2187.7% in Q1 2023.
- Quarterly Net Margin changed N/A year-over-year to 2187.7% in Q1 2023, while the trailing twelve-month figure through Dec 2023 was 4653.48% (changed N/A YoY) and the FY2023 annual result came in at 4653.48%, down 275464.0% from the prior year.
- Net Margin retreated to 2187.7% in Q1 2023, from 584.33% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 584.33% in Q3 2022 to a low of 2187.7% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Unicycive Therapeutics | 147.24 Mn | 147.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -2,187.70% |
| Sep 30, 2022 | -584.33% |